A significant up-regulation of Nfkb1 mRNA was observed in the group treated with orlistat compared to the obese control group, unlike what was reported (downregulation) by Wu et al. in 2016 [37] in a mouse model with colon cancer, suggesting that orlistat may ameliorate inflammatory effects through the inhibition of Nfkb1 and Stat3 [66]. The gene discussed is NFKB1; the disease is malignant colon neoplasm.